NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Assessment of the Quality of Life of Multiple Sclerosis Patients Treated With Ofatumumab in Real-life in France

Active Not RecruitingN/A

Sponsor: Novartis Pharmaceuticals

Conditions: Multiple Sclerosis (MS)

Interventions: ofatumumab

Countries: France

SEPROS is a non-interventional study, based on primary data collection of MS adult patients who initiated ofatumumab as per neurologist practice and regardless of the study protocol.

Eligibility overview

Sex: ALL

Age: 18 Years to 99 Years

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

1. Male or female, 18 years of age or older
2. Patient with confirmed MS diagnosis
3. Patient initiating treatment with ofatumumab for the first time
4. Patient for which the decision to initiate treatment with ofatumumab was made by the doctor (investigator) in accordance with his/her usual practices independently of the study
5. Patient not opposed to participation in this study
6. Patient willing and able to complete patient questionnaires

Exclusion Criteria:

1\. Patient treated with ofatumumab in the context of a clinical trial

Locations (49)

Angers, France, France
Paris, France, France
Agen, France
Altkirch, France
Amiens, France
Belfort, France
Bordeaux, France
Boulogne-sur-Mer, France
Brest, France
Brunstatt Didenheim, France
Cahors, France
Chambéry, France
Cherbourg Octeville, France
Compiègne, France
Contamine-sur-Arve, France
Dax, France
Gonesse, France
Le Bouscat, France
Le Coudray, France
Lens, France
Libourne, France
Lille, France
Lille, France
Lyon, France
Lyon, France
Mantes-la-Jolie, France
Marseille 01, France
Meaux, France
Metz-Tessy, France
Mont-de-Marsan, France
+ 19 more on CT.gov